UCF Researchers Work to Cut Away Brain Plaque Linked to Alzheimer’s Disease

By  //  December 6, 2019

Share on Facebook Share on Twitter Share on LinkedIn Share on Delicious Digg This Stumble This

Team’s findings hopes to offset disease’s devastating symptoms

UCF College of Medicine researchers have found an enzyme that cuts away the building blocks that form brain plaques linked to Alzheimer’s disease. (UCF image)

ORLANDO, FLORIDA – UCF College of Medicine researchers have found an enzyme that cuts away the building blocks that form brain plaques linked to Alzheimer’s disease.

Scientists believe the buildup of that plaque is what causes the disease’s devastating symptoms of cognitive decline, dementia and memory loss.

Worldwide, an estimated 44 million people experience Alzheimer’s – including 1 in 10 people 65 or older in the United States. As scientists seek to find a cure, they are focusing on the molecular changes that happen in the aging brain that could cause the disease.

They know that the brain’s amyloid precursor protein, responsible for growing and repairing brain cells, also releases amyloid beta peptides, which if out of control can clump together to form Alzheimer’s amyloid plaques.

Li-Mei Chen and Karl Chai had earlier discovered that an enzyme called matriptase can cut and disable individual amyloid beta peptides.

Now they are examining whether matriptase can cut and remove plaques from the brain without damaging surrounding tissues.

The researchers first discovered the enzyme’s cutting ability in 2011 as part of their efforts to treat breast cancer.

The researchers first discovered the enzyme’s cutting ability in 2011 as part of their efforts to treat breast cancer. Matriptase is found in human milk and has the ability to cut proteins found in breasts and many tumors.

But because their focus was on cancer, not Alzheimer’s, Chen and Chai didn’t follow up on their discovery until they read another researcher’s paper in 2017.

NASA Funds Two University of Central Florida Projects Focused on Returning to the MoonRelated Story:
NASA Funds Two University of Central Florida Projects Focused on Returning to the Moon

The paper, which appeared in the Journal of Biological Chemistry, discussed the enzyme’s potential uses in Alzheimer’s treatment.

That caused the team to revisit its work. They published a short report to inform and seek collaboration with other scientists.

This month they formed a collaboration with the authors of that study, Richard Leduc and Christine Lavoie at the Université de Sherbrooke in Quebec, Canada.

Although more research is needed, the enzyme appears promising in battling against Alzheimer’s disease.

UCF biomedical sciences undergraduate Jonathan Ruiz has been working with the research team since 2018. He said that in the lab, matriptase cut and disabled amyloid beta clumps in just a few hours.

“To be able to contribute alongside so many other researchers to find new potential ways to fight Alzheimer’s disease has been an amazing experience,” says Ruiz, who hopes to attend UCF medical school after graduating next summer.

The team published its findings earlier this year in the journal BMC Research Notes. The researchers said the next step will be to test the enzyme on specific cell lines and mouse models to see if “matriptase can selectively cut away plaque-forming proteins and the plaques without harming the cells in the brain,” Chen said.

There is no cure for Alzheimer’s, only medications to slow its progression. But those medications have major side effects, such as nausea, vomiting and loss of appetite.

The UCF researchers are now working to develop immune cells that could deliver matriptase directly to the brain. That treatment could potentially prevent Alzheimer’s and also improve brain function of patients with the disease, they said.

Outbreak of E. Coli Infections Linked to Romaine Lettuce, CDC Gives Tips on What to DoRelated Story:
Outbreak of E. Coli Infections Linked to Romaine Lettuce, CDC Gives Tips on What to Do

Chen received her medical training in Xiangya School of Medicine in Central South University of China and her doctorate in biochemistry and molecular biology from the Medical University of South Carolina.

Chai received his B.S. in biochemistry from Peking University in Beijing, and his doctorate in biochemistry and molecular biology from the Medical University of South Carolina.

They joined UCF in 1996, and have been conducting research on proteolytic enzymes relating to cancer, inflammation and immune disorders.

Leave a Comment